These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19572232)

  • 21. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.
    Bilimoria KY; Talamonti MS; Tomlinson JS; Stewart AK; Winchester DP; Ko CY; Bentrem DJ
    Ann Surg; 2008 Mar; 247(3):490-500. PubMed ID: 18376195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.
    Quek ML; Nichols PW; Yamzon J; Daneshmand S; Miranda G; Cai J; Groshen S; Stein JP; Skinner DG
    J Urol; 2005 Jul; 174(1):93-6. PubMed ID: 15947585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A; Wanek LA; Morton DL
    J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
    Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
    Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and prognostic features of rectal neuroendocrine tumors.
    Weinstock B; Ward SC; Harpaz N; Warner RR; Itzkowitz S; Kim MK
    Neuroendocrinology; 2013; 98(3):180-7. PubMed ID: 24080744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
    Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
    Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.
    Hassan I; You YN; Shyyan R; Dozois EJ; Smyrk TC; Okuno SH; Schleck CD; Hodge DO; Donohue JH
    Ann Surg Oncol; 2008 Jan; 15(1):52-9. PubMed ID: 18000711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital.
    Rothenstein J; Cleary SP; Pond GR; Dale D; Gallinger S; Moore MJ; Brierley J; Siu LL
    Am J Clin Oncol; 2008 Feb; 31(1):64-70. PubMed ID: 18376230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea.
    Lim T; Lee J; Kim JJ; Lee JK; Lee KT; Kim YH; Kim KW; Kim S; Sohn TS; Choi DW; Choi SH; Chun HK; Lee WY; Kim KM; Jang KT; Park YS
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):293-9. PubMed ID: 21884442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.
    Dabaja BS; Suki D; Pro B; Bonnen M; Ajani J
    Cancer; 2004 Aug; 101(3):518-26. PubMed ID: 15274064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
    Scigliano S; Lebtahi R; Maire F; Stievenart JL; Kianmanesh R; Sauvanet A; Vullierme MP; Couvelard A; Belghiti J; Ruszniewski P; Le Guludec D
    Endocr Relat Cancer; 2009 Sep; 16(3):977-90. PubMed ID: 19470616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
    Allan B; Davis J; Perez E; Lew J; Sola J
    Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors in neuroendocrine tumours of the lung: a single-centre experience.
    Filosso PL; Ruffini E; Di Gangi S; Guerrera F; Bora G; Ciccone G; Galassi C; Solidoro P; Lyberis P; Oliaro A; Sandri A
    Eur J Cardiothorac Surg; 2014 Mar; 45(3):521-6; discussion 526. PubMed ID: 24092506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.